Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results